Statins decrease mean platelet volume irrespective of cholesterol lowering effect

Kardiologia Polska

Volumn 71, Issue 10, 2013, Pages 1042-1047

  Sivri, Nasir ^a   Tekin, Gulacan ^b   Yalta, Kenan ^a   Aksoy, Yuksel ^a   Senen, Kubilay ^a   Yetkin, Ertan ^c  

^a TRAKYA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b BOZOK UNIVERSITY   (Turkey)

^c Middle East Hospital   (Turkey)

Author keywords

Mean platelet volume; Platelet activation; Statin

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SMOKING; THROMBOCYTE ACTIVATION; THROMBOCYTE VOLUME;

ADULT; CHOLESTEROL, LDL; COMORBIDITY; CORONARY DISEASE; DIABETES MELLITUS; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MEAN PLATELET VOLUME; MIDDLE AGED; PYRIMIDINES; PYRROLES; RETROSPECTIVE STUDIES; SULFONAMIDES;

EID: 84888242522     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: 10.5603/kp.2013.0259     Document Type: Article

References (33)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
2. Schwartz GG, Olsson AG, Ezekowitz MD et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. JAMA, 2001;285:1711-1718.
3. de Lemos JA, Blazing MA, Wiviott SD et al. A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes (phase Z of the A to Z trial). JAMA, 2004;292:1307-1316.
4. Ray KK. Cannon CP. McCabe CH et al. PROVE IT-TIMI 22 Investigators. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol, 2005;46:1405-1410.
5. Pasceri V, Patti G, Nusca A et al. ARMYDA Investigators Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) study. Circulation, 2004;110:674-678.
6. Koh KK. Effects of HMG-CoA reductase inhibitor on hemostasis. Int J Cardiol, 2000;76:23-32.
7. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol, 2001;21:1712-1719.
8. Thompson PD, Moyna NM, Michael White C et al. The effects of hydroxy-methyl-glutaryl co-enzyme A reductase inhibitors on platelet thrombus formation. Atherosclerosis, 2002;161:301-306.
9. Inoue I, Goto S, Mizotani K et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci, 2000;67:863-876.
10. Sukhova GK, Williams JK, Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol, 2002;22:1452-1458.
11. Shimada K, Miyauchi K, Daida H. Early intervention with atorvastatin modulates TH1/TH2 imbalance in patients with acute coronary syndrome: from bedside to bench. Circulation, 2004;109:e213-e214.
12. Rezaie-Majd A, Maca T, Bucek RA et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol, 2002;22:1194-1199.
13. Bickel C, Rupprecht HJ, Blankenberg S et al. AtheroGene Group. Influence of HMGCoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. Int J Cardiol, 2002;82:25-31.
14. Porreca E, Di Febbo C, Amore C et al. Effect of lipid-lowering treatment on factor VII profile in hyperlipidemic patients. Thromb Haemost, 2000;84:789-793.
15. Undas A, Brummel KE, Musial J et al. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation, 2001;103:2248-2253.
16. Undas A, Brummel-Ziedins KE, Potaczek DP et al. Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy. J Thromb Haemost, 2006;11:2397-2404.
17. Masamura K, Oida K, Kanehara H et al. Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family. Arterioscler Thromb Vasc Biol, 2003;23:512-517.
18. Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol, 2000;20:556-562.
19. Zhou Q, Liao JK. Pleiotropic effects of statins. Circ J, 2010;74:818-826
20. Martin JF, Trowbridge EA, Salmon G et al. The biological significance of platelet volume: its relationship to bleeding time, thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res, 1983;32:443-460.
21. Gaddam V, Li DY, Mehta JL. Anti-thrombotic effects of atorvastatin - an effect unrelated to lipid lowering. J Cardiovasc Pharmacol Ther, 2002;7:247-253.
22. Puccetti L, Bruni F, Bova G et al. Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects. Nutr Metab Cardiovasc Dis, 2001;11:378-387.
23. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-430.
24. Takemoto M, Liao J. Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase inhibitors. Arterioscler Thromb Vasc Biol, 2001;21:1712-1719.
25. Laufs U, Gertz K, Huang P et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke, 2000;31:2442-2449.
26. Haramaki N, Ikeda H, Takenaka K et al. Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: possible improvement of intraplatelet redox imbalance via HMG-CoA reductase. Arterioscler Thromb Vasc Biol, 2007;27:1471-1477.
27. Ali FY, Armstrong PC, Dhanji AR et al. Antiplatelet actions of statins and fibrates are mediated by PPARs. Arterioscler Thromb Vasc Biol, 2009;29:706-711.
28. Coban E, Afacan B. The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment. Platelets, 2008;19:111-114.
29. Endler G, Klimesch A, Sunder-Plassmann H et al. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol, 2002;117:399-404.
30. Martin JF, Bath PMW, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet, 1991;338:1409-1411.
31. Pizzulli L, Yang A, Martin JF et al. Changes in platelet size and count in unstable angina compared to stable angina or noncardiac chest pain. Eur Heart J, 1998;19:80-84.
32. Senaran H, Ileri M, Altinbag A et al. Thrombopoietin and mean platelet volume in coronary artery disease. Clin Cardiol, 2001;24:405-408.
33. Yetkin E. Mean platelet volume not so far from being a routine diagnostic and prognostic measurement. Thromb Haemost, 2008;100:3-4.